We use cookies to customise content for your subscription and for analytics.
If you continue to browse Lexology, we will assume that you are happy to receive all our cookies. For further information please read our Cookie Policy.

Search results

Order by: most recent most popular relevance



Results: 1-10 of 146

Novopharm v. Abbott; appeal of 55.2 proceeding; June 28, 2007; lansoprazole
  • Gowling Lafleur Henderson LLP
  • Canada
  • July 13 2007

The Federal Court of Appeal dismissed the generic company's appeal of a decision granting prohibition


Eli Lilly v. Apotex
  • Gowling Lafleur Henderson LLP
  • Canada
  • May 4 2009

The Court dismissed the application for prohibition on the basis that the allegations of anticipation, obviousness, claims broader and Gillette defence are justified


Merck v. Pharmascience, PMNOC Regulations decision
  • Gowling Lafleur Henderson LLP
  • Canada
  • May 21 2010

The Court, in a lengthy decision, dismissed an application for prohibition in respect of the drug finasteride, wherein allegations of invalidity had been raised, including grounds of double-patenting, novelty and obviousness


Abbott Laboratories Limited et al. v. The Minister of Health et al
  • Gowling Lafleur Henderson LLP
  • Canada
  • December 20 2007

In this decision, the Court again dismissed a motion by an innovator to reverse the order of evidence in a 55.2 proceeding


Sanofi-Aventis v Riva, preliminary motion to dismiss a judicial review proceeding; November 7, 2007 - rampiril
  • Gowling Lafleur Henderson LLP
  • Canada
  • December 6 2007

The Minister of Health had sent a letter to the generic company indicating that once it had satisfied the requirements of the NOC Regulations, it would be eligible to receive a NOC regardless of whether the other generic company to which it had cross-referenced its submission had satisfied all of the NOC Regulations and received a NOC


Apotex v. Adir
  • Gowling Lafleur Henderson LLP
  • Canada
  • July 27 2009

The Court of Appeal upheld the decision of the Trial Division finding that the patent was both valid and infringed


Federal court affirms standing for innovative drug manufacturer
  • Gowling Lafleur Henderson LLP
  • Canada
  • July 23 2014

What rights do innovative drug manufacturers have in situations where generics challenge certain Health Canada decisions but do not name the


Recent cases
  • Gowling Lafleur Henderson LLP
  • Canada
  • August 1 2008

The Court of Appeal overturned the motions judge's decision striking the notice of appearance


PMPRB issues discussion paper on options to address the Federal Court decision in LEO Pharma
  • Gowling Lafleur Henderson LLP
  • Canada
  • February 6 2008

The Patented Medicine Prices Review Board (PMPRB) has issued a discussion paper outlining a series of options to address the implications of the Federal Court of Canada decision in the LEO Pharma case


Data protection: defining innovative drug in Canada
  • Gowling Lafleur Henderson LLP
  • Canada
  • April 22 2013

Canada amended its Data Protection Regulations in 2006 to provide protection for innovative drugs in a second attempt to implement Canada's 1994